Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pharmathen

- PMLiVE

Empliciti on track for European approval in multiple myeloma

CHMP backs BMS and AbbVie's therapy after an accelerated assessment

- PMLiVE

Merck & Co’s oral hepatitis C therapy approved in US

Fixed-dose combination Zepatier wins a licence from the FDA

EISAI

Eisai’s Lenvima gets FDA priority review for kidney cancer

The oncology treatment could now be approved in the US before the summer

- PMLiVE

Baxalta agrees to $32bn Shire takeover

Deal will  create one of the industry's top rare disease firms

Shire Basingstoke

Shire deal with Baxalta predicted this week

Takeover talks reported to be at an advanced stage

EU flag

Nine positive opinions for new drugs at CHMP meeting

Tagrisso, Zurampic and Portrazza among the latest recommendations

- PMLiVE

Bayer defends Xarelto as pivotal trial scrutinised

ROCKET AF trial results questioned after some INRATIO devices used in testing recalled

EISAI

Eisai expands in China with generics company acquisition

BuysLiaoning TianYi Biological Pharmaceutical

EU flag

Wakix backed for European approval in narcolepsy

Bioprojet Pharma’s orphan drug given a positive opinion by CHMP

EU flag

EMA review clears GSK and Sanofi Pasteur MSD HPV vaccines

Concludes Cervarix andGardasil don’t cause CRPS or POTS

- PMLiVE

FDA approves Merrimack’s pancreatic cancer drug

Onivyde improves overall survival rates

- PMLiVE

Consultation begins on new patient access scheme

EMA hopes PRIME will improve development of prioritymedicines and ease access concerns

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links